Armata Pharmaceuticals Inc (ARMP) Reports Q3 2023 Financial Results and Corporate Updates
Continued Progress in Phage Therapeutics Development Amidst Increased Expenses
Source: yahoo.com
Stay updated with breaking news from E3 2022. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Continued Progress in Phage Therapeutics Development Amidst Increased Expenses
Net Revenue Rises as Company Advances with UGN-102 Clinical Development
Strategic Acquisitions and Product Launches Propel Growth Amidst Operational Challenges
Net Sales Surge by 128% Year-Over-Year; Company Raises Full-Year Revenue Guidance
Company's cash runway extended into 2026, with a net loss of $24.0 million for Q3 2023